{"entity":{"id":"tfap4","kind":"target","name":"TFAP4","aka":["transcription factor AP-4","Transcription factor AP-4","AP-4","bHLHc41"],"tldr":"TFAP4 (Transcription factor AP-4) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma and Burkitt lymphoma.","summary":"Transcription factor that activates both viral and cellular genes by binding to the symmetrical DNA sequence 5'-CAGCTG-3'.\n\nCIViC holds 1 clinical evidence item and 0 assertions across 1 variant. IntOGen calls it a driver in 3 cohorts (2 activating, 1 loss-of-function), covering Burkitt Lymphoma, Non-Hodgkin Lymphoma.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:11745","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11745"},{"label":"UniProt Q01664","url":"https://www.uniprot.org/uniprotkb/Q01664/entry"},{"label":"NCBI Gene 7023","url":"https://www.ncbi.nlm.nih.gov/gene/7023"},{"label":"Ensembl ENSG00000090447","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000090447"}],"tags":["cancer-genes-wave"],"related":["civic","intogen"],"cancers":["non-hodgkin-lymphoma","burkitt-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 2 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; CIViC holds 1 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"TFAP4","role":["oncogene-driver","tumour-suppressor","biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:11745","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11745","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt Q01664","url":"https://www.uniprot.org/uniprotkb/Q01664/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene TFAP4","url":"https://civicdb.org/features/5728","note":"1 evidence items, 0 assertions, 1 variants; diseases: Burkitt Lymphoma (GraphQL API, CC0)"},{"label":"IntOGen TFAP4","url":"https://www.intogen.org/search?gene=TFAP4","note":"driver in 3 cohorts (Act 2, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0"}],"specificity":"tumour-specific","distribution":"one-type","specificityNote":"Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA TFAP4: RNA low tissue specificity; high antibody staining in 5 normal tissues; highest cancer staining colorectal cancer (7 of 11 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Lymphoma); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)","specificitySources":[{"label":"UniProt Q01664","url":"https://www.uniprot.org/uniprotkb/Q01664/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene TFAP4","url":"https://civicdb.org/features/5728","note":"1 evidence items, 0 assertions, 1 variants; diseases: Burkitt Lymphoma (GraphQL API, CC0)"},{"label":"IntOGen TFAP4","url":"https://www.intogen.org/search?gene=TFAP4","note":"driver in 3 cohorts (Act 2, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0"},{"label":"Human Protein Atlas TFAP4 tissue","url":"https://www.proteinatlas.org/ENSG00000090447-TFAP4/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000090447 associations","url":"https://platform.opentargets.org/target/ENSG00000090447/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:11745","ensembl":"ENSG00000090447","uniprot":"Q01664","entrez":"7023","firstDescribed":1990,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Hu Y.-F. et al, Genes Dev, 1990, \"Transcription factor AP-4 contains multiple dimerization domains that regulate dimer specificity\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/2123466/","biology":"Transcription factor that activates both viral and cellular genes by binding to the symmetrical DNA sequence 5'-CAGCTG-3'. Location: Nucleus (UniProt). Locus 16p13.3 (HGNC).","whereFound":["Non-Hodgkin lymphoma: IntOGen driver in 1 cohort (NHL)","Burkitt lymphoma: CIViC evidence names this disease; IntOGen driver in 2 cohorts (BL)"],"targetClass":"transcription","prevalence":[]},"route":"/targets/tfap4/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"},{"id":"intogen","kind":"collection","name":"IntOGen","route":"/collections/intogen/"}],"cancer":[{"id":"burkitt-lymphoma","kind":"cancer","name":"Burkitt lymphoma","route":"/cancers/burkitt-lymphoma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}]}}